Biopharma group Lipoxen PLC (AIM: LPX) it has signed a new technology evaluation agreement with what it called a “leading global pharmaceutical company” for the use of Lipoxen's siRNAblate gene silencing technology platform in combination with the Pharma company's target siRNA.
SiRNA stands for small interfering RNA, but is sometimes referred to as short interfering RNA or silencing RNA.
Lipoxen, which specialises in developing differentiated biologicals, vaccines and siRNA delivery, said the partner company will fund and execute a programme to evaluate and analyse the effectiveness of combining the siRNAblate technology with its own siRNA, with the aim of enhancing efficacy of the siRNA via improved delivery.
This programme mirrors evaluation experiments with siRNA that Lipoxen has already successfully conducted and replicated in its own laboratories.
The evaluation programme is expected to be completed in the third quarter of 2009. If the evaluation is successful, the agreement may progress to a full development and licensing agreement.
Commenting on the deal, Scott Maguire, CEO of Lipoxen, said: “Lipoxen now has collaborations with some of the world's largest pharmaceutical companies across all three of our technology platforms. We are confident that the completion of this evaluation programme by a well known global pharmaceutical company will lead to further work on siRNA delivery, and potentially to a licensing deal."http://www.proactiveinvestors.co.uk
No comments:
Post a Comment